arXiv · 1907.05385
Brand vs. Generic: Addressing Non-Adherence, Secular Trends, and Non-Overlap
Abstract
While generic drugs offer a cost-effective alternative to brand name drugs, regulators need a method to assess therapeutic equivalence in a post market setting. We develop such a method in the context of assessing the therapeutic equivalence of immediate release (IM) venlafaxine, based on a large insurance claims dataset provided by OptumLabs\textsuperscript{\textregistered}. To properly address this question, our methodology must deal with issues of non-adherence, secular trends in health outcomes, and lack of treatment overlap due to sharp uptake of the generic once it becomes available. We define, identify (under assumptions) and estimate (using G-computation) a causal effect for a time-to-event outcome by extending regression discontinuity to survival curves. We do not find evidence for a lack of therapeutic equivalence of brand and generic IM venlafaxine.
Explore related subjects
Keep this discovery
Lamar Hunt III, Irene B. Murimi, Jodi B. Segal, Marissa J. Seamans, Daniel O. Scharfstein, Ravi Varadhan. 2019-07-07. Brand vs. Generic: Addressing Non-Adherence, Secular Trends, and Non-Overlap. https://arxiv.org/abs/1907.05385
Cite the original work for its findings. Save a collection to share your selection of sources.